A Single‑blind, Placebo‑controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC‑214870

Sponsor ID
325-201-00003
Clinicaltrials.gov ID
NCT04241965
EudraCT ID
N/A
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
N/A
Study Complete
Sponsor ID
325-201-00003
Trial Details
Subscribe for updates
Age
18 - 64 Years
Therapeutic Area
  • Epilepsy
    • Sex
    Female & Male
    Trial Dates
    Feb 2020 - Oct 2021
    Healthy Volunteers
    No
    • Male and female subjects between 18 and 64 years of age, inclusive.
    • Body mass index (BMI) between 18 and 40 kg/m\^2, inclusive.
    • Subjects with a diagnosis and history of photoparoxysmal response on EEG.
    • Subjects must be stable for 1 month prior to screening. Stable is defined as having no change in concomitant therapy and no worsening in the opinion of the investigator.
    • Subjects may be treatment-naïve to AEDs or currently treated with up to 3 AEDs.
    • Subjects must have a reproducible standardized photosensitivity range on EEG of at least 3 points in at least 1 eye condition.
    • Subjects who agree to remain abstinent, or practice double-barrier forms of birth control, from trial to screening through 90 days after the last dose of IMP, OR males and females of non-childbearing potential who are documented as sterile (i.e. male subjects who have undergone bilateral orchidectomy and female subjects who have undergone bilateral oophorectomy, bilateral salpingectomy, or hysterectomy, or who have been postmenopausal for at least 12 months.
    • History of non-epileptic seizures
    • History of status epilepticus in the past 5 years
    • An active central nervous system (CNS) infection, demyelinating disease, degenerative neurological disease, or any CNS disease deemed to be progressive during the course of the trial that may confound the interpretation of the trial results.
    • Positive urine drug screen for substance of abuse or upon check in to the trial site. Benzodiazepines are excluded as a drug of abuse, but are allowed as rescue medication or when part of subject's stable concomitant medication at enrollment.
    • History of drug and/or alcohol abuse within 24 months prior to screening.
    • Consumption of grapefruit, grapefruit juice, Seville oranges, or Seville orange juice within 7 days prior to dosing.
    • Consumption of more than 1 alcoholic drink within 24 hours prior to dosing. Food and beverages containing methylxanthines (caffeinated coffee, caffeinated tea, caffeinated soda, and chocolate) must remain stable throughout the trial.
    • Extreme physical activity within 24 hours before screening and visit
    • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving IMP
    • Subject having taken an investigational drug within 30 days preceding screening.
    • Use of over-the-counter drugs, herbal medicines, or vitamin supplements within 14 days or 5 half-lives, whichever is longer, prior to dosing and antibiotics within 30 days prior to dosing.
    • Subjects who had neurosurgery in last 6 months.
    • Subjects on a ketogenic diet.
    • History of significant sleep disorders, or any disorder or activity that causes sleep deprivation.
    • Subjects who work "night shifts"
    • Subjects with uncontrolled sleep disorders; subjects should be on a stable dose of sleep medications.
    • History of, or current hepatitis or acquired immunodeficiency syndrome or carriers of hepatitis B surface antigen (HBsAg), hepatitis C antibodies (anti-HCV), and/or HIV antibodies.

    Study Summary

    Despite availability of several antiepileptic drugs (AEDs), in one-third of patients, epilepsy remains uncontrolled with AEDs. There is a need to develop new approaches to improve the existing medications to relieve patients' epilepsy, and OPC-214870 is being studied for this purpose.

    Additional Study Details

    Phase
    Phase 1
    Study Drug
    Drug: OPC-214870
    Type
    Interventional
    Masking
    Single
    Estimated Enrollment
    16
    Additional Study Details

    Inclusion and Exclusion Criteria

    Inclusion Criteria

    • * Male and female subjects between 18 and 64 years of age, inclusive.
    • * Body mass index (BMI) between 18 and 40 kg/m\^2, inclusive.

    Exclusion Criteria

    • * History of non-epileptic seizures
    • * History of status epilepticus in the past 5 years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    • Male and female subjects between 18 and 64 years of age, inclusive.
    • Body mass index (BMI) between 18 and 40 kg/m\^2, inclusive.
    • Subjects with a diagnosis and history of photoparoxysmal response on EEG.
    • Subjects must be stable for 1 month prior to screening. Stable is defined as having no change in concomitant therapy and no worsening in the opinion of the investigator.
    • Subjects may be treatment-naïve to AEDs or currently treated with up to 3 AEDs.
    • Subjects must have a reproducible standardized photosensitivity range on EEG of at least 3 points in at least 1 eye condition.
    • Subjects who agree to remain abstinent, or practice double-barrier forms of birth control, from trial to screening through 90 days after the last dose of IMP, OR males and females of non-childbearing potential who are documented as sterile (i.e. male subjects who have undergone bilateral orchidectomy and female subjects who have undergone bilateral oophorectomy, bilateral salpingectomy, or hysterectomy, or who have been postmenopausal for at least 12 months.
    Exclusion Criteria:
    • History of non-epileptic seizures
    • History of status epilepticus in the past 5 years
    • An active central nervous system (CNS) infection, demyelinating disease, degenerative neurological disease, or any CNS disease deemed to be progressive during the course of the trial that may confound the interpretation of the trial results.
    • Positive urine drug screen for substance of abuse or upon check in to the trial site. Benzodiazepines are excluded as a drug of abuse, but are allowed as rescue medication or when part of subject's stable concomitant medication at enrollment.
    • History of drug and/or alcohol abuse within 24 months prior to screening.
    • Consumption of grapefruit, grapefruit juice, Seville oranges, or Seville orange juice within 7 days prior to dosing.
    • Consumption of more than 1 alcoholic drink within 24 hours prior to dosing. Food and beverages containing methylxanthines (caffeinated coffee, caffeinated tea, caffeinated soda, and chocolate) must remain stable throughout the trial.
    • Extreme physical activity within 24 hours before screening and visit
    • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving IMP
    • Subject having taken an investigational drug within 30 days preceding screening.
    • Use of over-the-counter drugs, herbal medicines, or vitamin supplements within 14 days or 5 half-lives, whichever is longer, prior to dosing and antibiotics within 30 days prior to dosing.
    • Subjects who had neurosurgery in last 6 months.
    • Subjects on a ketogenic diet.
    • History of significant sleep disorders, or any disorder or activity that causes sleep deprivation.
    • Subjects who work "night shifts"
    • Subjects with uncontrolled sleep disorders; subjects should be on a stable dose of sleep medications.
    • History of, or current hepatitis or acquired immunodeficiency syndrome or carriers of hepatitis B surface antigen (HBsAg), hepatitis C antibodies (anti-HCV), and/or HIV antibodies.

    Locations

    Location
    Status
    Location
    For additional information regarding sites, contact 844-687-8522
    Ormond Beach, Florida, United States, 34174
    Status
    N/A

    © 2026 Otsuka America Pharmaceutical, Inc.

    All rights reserved.

    January 2026 01US25EUC0489

    We defy limitation,

    so that others can too.

    Follow Us
    OAPI and OPDC Locations

    508 Carnegie Center Dr,

    Princeton, NJ 08540, United States

    Phone +1 609-524-6788

    2440 Research Blvd,

    Rockville, MD 20850, United States

    Phone +1 301-424-9055

    3956 Point Eden Way

    Hayward, CA 94545, United States

    Phone +1 800-562-3974